February 2, 2012
By:Birgit Schumacher, PhD, SGS Life Science Services
With many new challenges in early clinical development there is pressure to change how early phase clinical trials are conducted. It is increasingly important to consider and be creative about new designs and flexible implementation of new techniques. Case studies illustrated in this paper show how trial design and execution can successfully overcome these challenges.
 |
February 1, 2012
By:Stan Haavik, Medidata Solutions
A Medidata white paper examining the results of a survey and three case studies to provide insights on lowering the costs of clinical trials while still paying sites accurately.
|
January 20, 2012
By:SAS
Read about how automated data integration and validation can increase efficiency, speed time to market for new compounds – and cut costs. Managing clinical trials data and preparing clinical data for analysis have traditionally been cumbersome and resource-intensive, but some industry analysts believe that implementing data standards and automated processes can trim 30 to 50 percent from the trial cycle. This white paper makes a case for implementing data standards and applying automated processes for managing data throughout the clinical trials process, from study design to regulatory submissions.
|
January 20, 2012
By:SAS Institute
This white paper describes several key areas where SAS® analytical capabilities can bring significant efficiencies to the clinical research process. Read about how to optimize operations during the critical phases of trial design, site selection and monitoring, patient recruitment and clinical supply management.
|
January 20, 2012
By:SAS Institute
This white paper includes insights from clinical trial practitioners on the benefits of adaptive clinical trials over traditional fixed designs. It also discusses current barriers to the acceptance and general utilization of adaptive clinical trials, as well as what technology is available to enhance progress and acceptance.
|
January 14, 2012
By:Carolynn T. Jones, MSPH, RN, Penelope M.Jester, MPH, RN, Meredith Fitz-Gerald, BSN, RN, CenterWatch
Learn about site/sponsor responsibilities and effective strategies to manage protocol amendments.
|
January 1, 2012
By:Polina Voloshko, MD, Joseph McPhillips, Cardiocore
Cardiotoxicity is now recognized as a common adverse effect of many anti-neoplastic agents. Targeted anti-tumor therapies and cytotoxic, chemotherapeutic agents have an effect on both the cardiovascular system and the tumor.
|
January 1, 2012
By:ARX’s CoSign
The majority of large CROs and Pharmas are using digital signatures to speed clinical site initiation, reduce site monitoring reporting costs, and improve audit efficiency. See how digital signatures enable these benefits and others by allowing key players in the clinical ecosystem (site personnel, IRBs, CROs, sponsors) to electronically sign and submit reports and other documents.
|
November 14, 2011
By:Nancy Fuller, Senior Manager - Cognizant Business Consulting, Life Sciences Practice., Cognizant
Cognizant (NASDAQ: CTSH) is the preferred global services partner for the life sciences industry. In fact, 27 of the top 30 global pharmaceutical, 9 of the top 10 biotech and 12 of the top 20 medical device companies benefit from our integrated services portfolio. Cognizant enables business transformation by delivering information technology, consulting and business process outsourcing services to help you rationalize costs, enhance operational efficiencies, and improve business agility across all life sciences business processes.
|
| 
Facebook
